p53, guardian of the genome

Overview of attention for article published in Nature, July 1992

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

So far, Altmetric has seen 27 news stories from 27 outlets.

Selinexor治疗组与安慰剂组相比无进展生存期显著提高（HR=0.7；p = 0.0486） -p53野生型亚组患者的无进展生存期显著延长（HR=0.38, p=0.0006） -Selinexor耐受性良好，未发现新的安全性信号，且因不良事件停药发生率…

-Selinexor治療組與安慰劑組相比無進展生存期顯著提高（HR=0.7；p = 0.0486） -p53野生型亞組患者的無進展生存期顯著延長（HR=0.38, p=0.0006） -Selinexor耐受性良好，未發現新的安全性信號，且因不良事件停藥發生…

- Selinexor Demonstrates Statistically Significant 50% Improvement in Median Progression-Free Survival Compared to Placebo (Hazar…

NEWTON, Mass., Feb. 8, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 23 additional news stories.